Vib Vzw

Gent, Belgium
Gent, Belgium
SEARCH FILTERS
Time filter
Source Type

Patent
Vib Vzw and Ghent University | Date: 2017-05-17

The present invention relates to plants having a decreased expression of the KIX8 and KIX9 genes which result in an increased yield, particularly an increased leaf biomass. The invention provides plants and chimeric genes which can be used to decrease the combined KIX8/KIX9 gene expression.


Patent
Vib Vzw and Vrije Universiteit Brussel | Date: 2017-07-26

The invention relates to the field of structural biology. More specifically, the invention relates to methods for the identification and characterization of biomolecular tools allowing the selective recognition and/or stabilization of distinct conformational states of protein complexes, including transient protein-protein interactions and protein-nucleic acid complexes. Such tools can then be used for purification purposes, crystallization and structure determination of these stabilized protein complexes, for drug discovery, as research tools, as well as for diagnosis and treatment of diseases.


Patent
Vib Vzw, Life Sciences Partners and Ghent University | Date: 2017-04-10

Described are nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. These are particularly useful for applications using gene therapy.


Patent
Vib Vzw and Catholic University of Leuven | Date: 2017-01-18

The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies which bind to BACE1 and methods using these antibodies. Said antibodies can be used for research and medical applications.


Patent
Vib Vzw, Vrije Universiteit Brussel and Stanford University | Date: 2017-01-18

The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.


Patent
Vib Vzw, Ghent University, The United States Of America and Dartmouth College | Date: 2017-02-01

The present invention relates to single domain antibodies that are directed against respiratory syncytial virus (RSV). More specifically, it relates to single domain antibodies that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these single domain antibodies for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these single domain antibodies.


Patent
Swetree Technologies AB, Vib Vzw and Ghent University | Date: 2017-06-28

The invention relates to methods for producing a plant with altered lignin content by genetically manipulating expression of a PIRIN gene. The said method comprises (a) altering expression of a gene encoding a PIRIN2 polypeptide in the plant; and/or (b) altering expression of a gene encoding a PIRIN4 polypeptide in the plant. A plant with reduced lignin content is produced by increasing expression of a gene encoding a PIRIN2 polypeptide in the plant or decreasing expression of a gene encoding a PIRIN4 polypeptide in the plant. The invention further relates to genetically modified plants produced by the said methods.


Patent
Ghent University and Vib Vzw | Date: 2017-02-08

The present invention provides compositions and methods comprising a sialoadhesin binding moiety for treating metabolic and genetic bone disease, especially for treating a bone disorder of hyperresorption of bone and/or enhanced activation of osteoclasts.


Patent
Vib Vzw and Catholic University of Leuven | Date: 2017-04-05

The present invention relates to the use of GLO1 to modulate acetic acid tolerance in yeast. More specifically, it relates to the use of a specific GLO1 allele to confer tolerance to acetic acid, and to improve the fermentation performance of yeast in the presence of acetic acid.


Patent
Hoffmann-La Roche, Vib Vzw and Life Sciences Partners | Date: 2017-04-12

The present invention relates to methods for improving the overall survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the vascular endothelial growth factor receptor 1 (VEGFR-1) gene. The present invention further provides methods for improving the progression-free survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the VEGFR-1 gene. The present invention also provides for methods for assessing the responsiveness of a patient to an angiogenesis inhibitor by determining the presence of one or more variant alleles of the VEGFR-1 gene.

Loading Vib Vzw collaborators
Loading Vib Vzw collaborators